BREAST CANCER

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.

Data presented at ESMO Targeted Anticancer Therapies Congress 2026 support ongoing phase 3 evaluation.

Breast cancer care shifts fast: ADCs reach HER2-low, neoadjuvant regimens evolve, and ctDNA MRD testing sparks 2026’s debate.

AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.

Gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS in HR+/HER2− PIK3CA WT breast cancer after CDK4/6.

How GLP-1 weight-loss drugs fit after breast cancer: emerging survival hints, new ESMO cautions during chemo, and smart tapering to avoid rebound.

Results from the 992-patient study will be presented at an upcoming medical meeting; FDA review of giredestrant is ongoing based on data from the positive evERA trial.

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

Compare T-DXd, sacituzumab, and dato-DXd in HR+ metastatic breast cancer—key trial results, side effects, and sequencing insights.

FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.

New data push the use of ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategies.

FDA clears real-time AI OCT to spot breast cancer margins during lumpectomy, helping surgeons reduce repeat operations and improve outcomes.

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Phase 3 interim data show izalontamab brengitecan boosts survival in pretreated metastatic triple‑negative breast cancer, hinting at new standard.

FDA fast tracks ART6043, an oral Polθ inhibitor for gBRCA HER2-negative metastatic breast cancer, showing early activity and potential to overcome PARP resistance.

FDA reviews oral giredestrant plus everolimus for ESR1-mutated ER+ metastatic breast cancer after CDK4/6 failure, with strong PFS gains and manageable safety.

How ancestry, neighborhood stress and chemo side effects shape TNBC outcomes—and why immunotherapy and tailored care can narrow survival gaps.

During a virtual event, Aditya Bardia, MD, MPH and participants weigh elacestrant and imlunestrant, comparing real-world adverse effects and efficacy.

TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem

FDA prioritizes review of datopotamab deruxtecan for treating metastatic triple-negative breast cancer, showing significant survival benefits over chemotherapy.

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

NCCN updates guidelines to include sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer, enhancing patient options.